Natalizumab: a new therapy for acute ischemic stroke?

References

• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–e292.
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:789–799.
   PubMed Web of Science ®Google Scholar
• Fiehler J, Gerloff C. Mechanical thrombectomy in stroke. Dtsch Arztebl Int. 2015;112:830–836.
   PubMed Web of Science ®Google Scholar
• Turner RC, Dodson SC, Rosen CL, et al. The science of cerebral ischemia and the quest for neuroprotection: navigating past failure to future success. J Neurosurg. 2013;118:1072–1085.
   PubMed Web of Science ®Google Scholar
• O’Collins VE, Macleod MR, Donnan GA, et al. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006;59:467–477.
   PubMed Web of Science ®Google Scholar
• Simats A, García-Berrocoso T, Montaner J. Neuroinflammatory biomarkers: from stroke diagnosis and prognosis to therapy. Biochim Biophys Acta. 2015;1862:411–424.
   PubMed Web of Science ®Google Scholar
• Connolly ES, Winfree CJ, Springer TA, et al. Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest. 1996;97:209–216.
   PubMed Web of Science ®Google Scholar
• Jiang N, Chopp M, Chahwala S. Neutrophil inhibitory factor treatment of focal cerebral ischemia in the rat. Brain Res. 1998;788:25–34.
   PubMed Web of Science ®Google Scholar
• Perez-de-Puig I, Miró-Mur F, Ferrer-Ferrer M, et al. Neutrophil recruitment to the brain in mouse and human ischemic stroke. Acta Neuropathol. 2015;129:239–257.
   PubMed Web of Science ®Google Scholar
• Emerich DF, Dean RL, Bartus RT. The role of leukocytes following cerebral ischemia: pathogenic variable or bystander reaction to emerging infarct? Exp Neurol. 2002;173:168–181.
   PubMed Web of Science ®Google Scholar
• Matsuo Y, Onodera H, Shiga Y, et al. Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat. Effects of Neutrophil depletion. Stroke. 1994;25:1469–1475.
   PubMed Web of Science ®Google Scholar
• Rosell A, Ortega-Aznar A, Alvarez-Sabín J, et al. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke. 2006;37:1399–1406.
   PubMed Web of Science ®Google Scholar
• Rosell A, Cuadrado E, Ortega-Aznar A, et al. MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke. 2008;39:1808–1813.
   PubMed Web of Science ®Google Scholar
• Chen H, Chopp M, Bodzin G. Neutropenia reduces the volume of cerebral infarct after transient middle cerebral occlusion in the rat. Neurosci Res Commun. 1992;11:93–99.
   Google Scholar
• Shimakura A, Kamanaka Y, Ikeda Y, et al. Neutrophil elastase inhibition reduces cerebral ischemic damage in the middle cerebral artery occlusion. Brain Res. 2000;858:55–60.
   PubMed Web of Science ®Google Scholar
• Enzmann G, Mysiorek C, Gorina R, et al. The neurovascular unit as a selective barrier to polymorphonuclear granulocyte (PMN) infiltration into the brain after ischemic injury. Acta Neuropathol. 2013;125:549–564.
   PubMed Web of Science ®Google Scholar
• Toft-Hansen H, Buist R, Sun X-J, et al. Metalloproteinases control brain inflammation induced by pertussis toxin in mice overexpressing the chemokine CCL2 in the central nervous system. J. Immunol. 2006;177(10):7242–7249.
   PubMed Web of Science ®Google Scholar
• Bartholomäus I, Kawakami N, Odoardi F, et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature. 2009 Nov;462:94–98.
   PubMed Web of Science ®Google Scholar
• Liesz A, Zhou W, Mracskó É, et al. Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. Brain. 2011;134:1077–1088.
   PubMed Web of Science ®Google Scholar
• Yilmaz G, Arumugam TV, Stokes KY, et al. Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation. 2006;113:2105–2112.
   PubMed Web of Science ®Google Scholar
• Kleinschnitz C, Schwab N, Kraft P, et al. Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation. Blood. 2010;115:3835–3842.
   PubMed Web of Science ®Google Scholar
• Shichita T, Sugiyama Y, Ooboshi H, et al. Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med. 2009;15:946–950.
   PubMed Web of Science ®Google Scholar
• Rüegg C, Postigo AA, Sikorski EE, et al. Role of integrin alpha4beta7/alpha4betaP in lymphocyte adherence to fibronectin and VCAM-1 and in homotypic cell clustering. J Cell Biol. 1992;117:179–189.
   PubMed Web of Science ®Google Scholar
• Engelhardt B, Conley FK, Kilshaw PJ, et al. Lymphocytes infiltrating the CNS during inflammation display a distinctive phenotype and bind to VCAM-1 but not to MAdCAM-1. Int Immunol. 1995;7:481–491.
   PubMed Web of Science ®Google Scholar
• González-Amaro R, Mittelbrunn M, Sánchez-Madrid F. Therapeutic anti-integrin (α4 and αL) monoclonal antibodies: two-edged swords? Immunology. 2005;116:289–296.
   PubMed Web of Science ®Google Scholar
• Cook-Mills JM, Marchese ME, Abdala-Valencia H. Vascular cell adhesion molecule-1 expression and signaling during disease: regulation by reactive oxygen species and antioxidants. Antioxid Redox Signal. 2011;15:1607–1638.
   PubMed Web of Science ®Google Scholar
• Biogen. TYSABRI (Natalizumab). U.S. Patent Numbers: 5,840,299; 6,602,503. 2015.
   Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of Natalizumab for relapsing multiple sclerosis. N Engl J Med. 2014;354:981–992.
   Google Scholar
• Mattoscio M, Nicholas R, Sormani MP, et al. Hematopoietic mobilization: potential biomarker of response to natalizumab in multiple sclerosis. Neurology. 2015;84:1473–1482.
   PubMed Web of Science ®Google Scholar
• Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology. 2011;76(20):1697–1704.
   PubMed Web of Science ®Google Scholar
• Clifford DB, DeLuca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9(4):438–446.
   PubMed Web of Science ®Google Scholar
• del Zoppo GJ. Acute anti-inflammatory approaches to ischemic stroke. Ann NY Acad Sci. 2010;1207:143–148.
   PubMed Web of Science ®Google Scholar
• Furuya K, Takeda H, Azhar S, et al. Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody. Stroke. 2001;32:2665-2674.
   Google Scholar
• Becker K, Kindrick D, Relton J, et al. Antibody to the alpha-4 integrin decreases infarct size in transient focal cerebral ischemia in rats. Stroke. 2001;32:206–211.
   PubMed Web of Science ®Google Scholar
• Relton JK, Sloan KE, Frew EM, et al. Inhibition of alpha-4 integrin protects against transient focal cerebral ischemia in normotensive and hypertensive rats. Stroke. 2001;32:199–205.
   PubMed Web of Science ®Google Scholar
• Neumann J, Riek-Burchardt M, Herz J, et al. Very-late-antigen-4 (VLA-4)-mediated brain invasion by neutrophils leads to interactions with microglia, increased ischemic injury and impaired behavior in experimental stroke. Acta Neuropathol. 2015;129:259–277.
   PubMed Web of Science ®Google Scholar
• Langhauser F, Kraft P, Göb E, et al. Blocking of α4 integrin does not protect from acute ischemic stroke in mice. Stroke. 2014;45:3454–3460.
   PubMed Web of Science ®Google Scholar
• Llovera G, Hofmann K, Roth S, et al. Results of a preclinical randomized controlled multicenter trial (pRCT): anti-CD49d treatment for acute brain ischemia. Sci Transl Med. 2015;7:299ra121.
   PubMed Web of Science ®Google Scholar
• Elkins J, Elkind MS, Veltkamp R, et al. LB22. Primary results of the ACTION trial of Natalizumab in acute ischemic stroke (AIS). Presented at: International Stroke Conference; 2016 Feb 16-19; Los Angeles.
   Google Scholar
• Liu J, Zhang C, Tao W, et al. Systematic review and meta-analysis of the efficacy of sphingosine-1-phosphate (S1P) receptor agonist FTY720 (fingolimod) in animal models of stroke. Int J Neurosci. 2013;123:163–169.
   PubMed Web of Science ®Google Scholar
• Fu Y, Zhang N, Ren L, et al. Impact of an immune modulator fingolimod on acute ischemic stroke. Proc Natl Acad Sci USA. 2014;111:18315–18320.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Fu Y, Tian D, et al. Combination of the immune modulator Fingolimod with Alteplase in acute ischemic stroke: a pilot trial. Circulation. 2015;132:1104–1112.
   PubMed Web of Science ®Google Scholar
• Mulcahy NJ, Ross J, Rothwell NJ, et al. Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br J Pharmacol. 2003;140:471–476.
   PubMed Web of Science ®Google Scholar
• Maysami S, Wong R, Pradillo JM, et al. A cross-laboratory preclinical study on the effectiveness of interleukin-1 receptor antagonist in stroke. J Cereb Blood Flow Metab. 2016;36:596–605.
   PubMed Web of Science ®Google Scholar
• Ayuso MI, Montaner J. Advanced neuroprotection for brain ischemia: an alternative approach to minimize stroke damage. Expert Opin Investig Drugs. 2015;24:1137–1142.
   PubMed Web of Science ®Google Scholar